Amgen sues Apotex over Sensipar generic

Amgen has filed a complaint against Apotex for allegedly infringing a patent centring on Sensipar (cinacalcet hydrochloride) tablets.

Sensipar is a treatment for secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

The case arose after Apotex filed an Abbreviated New Drug Application (ANDA) seeking approval to manufacture a generic version of the drug before US patent number 9,375,405 expires.

The case was filed on Tuesday, October 11, in the US District Court for the District of Delaware.

Amgen is asking the court to uphold the validity of its patent, prevent Apotex from bringing the generic to market, and be awarded costs, expenses and attorneys’ fees.

Amgen has also previously sued Cipla, Dr Reddy’s, Ajanta Pharma and Micro Labs for alleged patent infringement over Sensipar.